US4657760A
(en)
|
1979-03-20 |
1987-04-14 |
Ortho Pharmaceutical Corporation |
Methods and compositions using monoclonal antibody to human T cells
|
DK187280A
(da)
|
1980-04-30 |
1981-10-31 |
Novo Industri As |
Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
US5567610A
(en)
|
1986-09-04 |
1996-10-22 |
Bioinvent International Ab |
Method of producing human monoclonal antibodies and kit therefor
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5225212A
(en)
|
1989-10-20 |
1993-07-06 |
Liposome Technology, Inc. |
Microreservoir liposome composition and method
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5229275A
(en)
|
1990-04-26 |
1993-07-20 |
Akzo N.V. |
In-vitro method for producing antigen-specific human monoclonal antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
KR100272077B1
(ko)
|
1990-08-29 |
2000-11-15 |
젠팜인터내셔날,인코포레이티드 |
이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
WO1993006217A1
(en)
|
1991-09-19 |
1993-04-01 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
JPH07501451A
(ja)
|
1991-11-25 |
1995-02-16 |
エンゾン・インコーポレイテッド |
多価抗原結合タンパク質
|
EP1997894B1
(en)
|
1992-02-06 |
2011-03-30 |
Novartis Vaccines and Diagnostics, Inc. |
Biosynthetic binding protein for cancer marker
|
US5573905A
(en)
|
1992-03-30 |
1996-11-12 |
The Scripps Research Institute |
Encoded combinatorial chemical libraries
|
AU668423B2
(en)
|
1992-08-17 |
1996-05-02 |
Genentech Inc. |
Bispecific immunoadhesins
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
DE69637481T2
(de)
|
1995-04-27 |
2009-04-09 |
Amgen Fremont Inc. |
Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
|
JP2002514895A
(ja)
|
1995-09-28 |
2002-05-21 |
アレクション、ファーマスーティカルズ、インコーポレーテッド |
ブタ細胞相互作用タンパク質
|
DE19544393A1
(de)
|
1995-11-15 |
1997-05-22 |
Hoechst Schering Agrevo Gmbh |
Synergistische herbizide Mischungen
|
EP2305027B1
(en)
|
1996-12-03 |
2014-07-02 |
Amgen Fremont Inc. |
Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
ES2375931T3
(es)
|
1997-12-05 |
2012-03-07 |
The Scripps Research Institute |
Humanización de anticuerpo murino.
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
AU4834999A
(en)
|
1998-06-26 |
2000-01-17 |
Incyte Pharmaceuticals, Inc. |
Human signal peptide-containing proteins
|
MXPA02003456A
(es)
|
1999-10-04 |
2002-10-23 |
Medicago Inc |
Metodo para regular la transcripcion de genes foraneos.
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
US6849425B1
(en)
*
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
JP2003531588A
(ja)
|
2000-04-11 |
2003-10-28 |
ジェネンテック・インコーポレーテッド |
多価抗体とその用途
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
US8231878B2
(en)
|
2001-03-20 |
2012-07-31 |
Cosmo Research & Development S.P.A. |
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
US20090081199A1
(en)
|
2001-03-20 |
2009-03-26 |
Bioxell S.P.A. |
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
CA2342376C
(en)
|
2001-03-20 |
2013-11-12 |
Marco Colonna |
A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
ATE423571T1
(de)
|
2001-10-12 |
2009-03-15 |
Schering Corp |
Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten
|
EP1508340A4
(en)
|
2002-05-24 |
2009-07-01 |
Takeda Pharmaceutical |
MEANS FOR IMPROVING INSULIN RESISTANCE
|
JP2004073182A
(ja)
|
2002-05-24 |
2004-03-11 |
Takeda Chem Ind Ltd |
インスリン抵抗性改善剤
|
JP2006504971A
(ja)
|
2002-11-01 |
2006-02-09 |
ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド,ア・ボディー・コーポレイト |
マトリックス支援レーザー脱離イオン化−飛行時間型質量分析によるタンパク質アイソフォームの定量的解析
|
CA2503390A1
(en)
|
2002-11-01 |
2004-05-21 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
ATE515514T1
(de)
|
2002-12-23 |
2011-07-15 |
Schering Corp |
Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
|
WO2004074506A2
(en)
|
2003-02-13 |
2004-09-02 |
Mergen Ltd |
Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
|
AP2007004034A0
(en)
|
2004-12-31 |
2007-06-30 |
Genentech Inc |
Polypeptides sthat bind br3 and uses thereof
|
US7700099B2
(en)
|
2005-02-14 |
2010-04-20 |
Merck & Co., Inc. |
Non-immunostimulatory antibody and compositions containing the same
|
US8101345B1
(en)
|
2005-03-25 |
2012-01-24 |
Isis Pharmaceuticals, Inc. |
Proinflammatory nucleic acids
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP2001490A1
(en)
|
2006-03-15 |
2008-12-17 |
Alexion Pharmaceuticals, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
DE202006007499U1
(de)
|
2006-05-11 |
2007-01-11 |
Osaka University |
Verwendung einer Zusammensetzung, die Plexin-A1-DAP12-Interaktion inhibiert, zur Behandlung von Entzündungs-, Autoimmun- oder Knochenresorptionserkrankungen
|
NZ612319A
(en)
|
2006-06-12 |
2015-04-24 |
Emergent Product Dev Seattle |
Single-chain multivalent binding proteins with effector function
|
WO2008042261A2
(en)
*
|
2006-09-28 |
2008-04-10 |
Elusys Therapeutics, Inc. |
Anti-anthrax antibody, formulations thereof, and methods of use
|
US7673853B2
(en)
|
2006-10-12 |
2010-03-09 |
Cordell Eldred Ebeling |
Fencing section with adjustable fencing members
|
UY30776A1
(es)
|
2006-12-21 |
2008-07-03 |
Medarex Inc |
Anticuerpos cd44
|
AU2008205538A1
(en)
*
|
2007-01-16 |
2008-07-24 |
Wyeth |
Inflammation treatment, detection and monitoring via TREM-1
|
AU2008298603B2
(en)
|
2007-09-14 |
2015-04-30 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
WO2009046313A2
(en)
|
2007-10-05 |
2009-04-09 |
University Of Maryland, Baltimore |
Novel compositions and methods for stimulating erythropoiesis in a mammal
|
KR100960684B1
(ko)
|
2008-02-22 |
2010-05-31 |
전남대학교산학협력단 |
Ga733-2 발현 억제제로서의 trem-2 유전자, 및 이를포함하는 형질전환 동물 및 이의 사용방법
|
EP2186928A1
(en)
|
2008-11-14 |
2010-05-19 |
Enthone, Inc. |
Method for the post-treatment of metal layers
|
FR2945538B1
(fr)
|
2009-05-12 |
2014-12-26 |
Sanofi Aventis |
Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
|
US8513185B2
(en)
|
2009-10-13 |
2013-08-20 |
Alexander B. Sigalov |
Inhibition of TREM receptor signaling with peptide variants
|
RU2580038C2
(ru)
|
2009-12-04 |
2016-04-10 |
Дженентек, Инк. |
Мультиспецифические антитела, аналоги антител, композиции и способы
|
TWI653333B
(zh)
*
|
2010-04-01 |
2019-03-11 |
安進研究(慕尼黑)有限責任公司 |
跨物種專一性之PSMAxCD3雙專一性單鏈抗體
|
DK2593594T3
(en)
|
2010-07-16 |
2017-12-11 |
Adimab Llc |
ANTIBODY LIBRARIES
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
US20120195900A1
(en)
|
2010-12-22 |
2012-08-02 |
Abbott Laboratories |
Tri-variable domain binding proteins and uses thereof
|
WO2012088302A2
(en)
|
2010-12-22 |
2012-06-28 |
Abbott Laboratories |
Half immunoglobulin binding proteins and uses thereof
|
TWI559929B
(en)
*
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
WO2014074942A1
(en)
|
2012-11-08 |
2014-05-15 |
Illumina, Inc. |
Risk variants of alzheimer's disease
|
CA2825821A1
(en)
|
2013-08-28 |
2015-02-28 |
Chiesi Farmaceutici S.P.A. |
1-phenylalkanecarboxylic acid derivatives for the treatment of alzheimer's disease and multiple sclerosis
|
WO2015037000A1
(en)
|
2013-09-11 |
2015-03-19 |
Compugen Ltd |
Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
|
US20170218091A1
(en)
|
2014-07-03 |
2017-08-03 |
Abbvie Inc. |
Monovalent binding proteins
|
SG10201913611QA
(en)
|
2014-08-08 |
2020-03-30 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
EP3197495A4
(en)
*
|
2014-09-28 |
2018-08-29 |
The Regents of The University of California |
Modulation of stimulatory and non-stimulatory myeloid cells
|
WO2016064895A1
(en)
*
|
2014-10-20 |
2016-04-28 |
The Brigham And Women's Hospital, Inc. |
Targeting apolipoprotein e (apoe) in neurologic disease
|
CA2981183A1
(en)
|
2015-04-07 |
2016-10-13 |
Greg Lazar |
Antigen binding complex having agonistic activity and methods of use
|
US20180200259A1
(en)
|
2015-05-18 |
2018-07-19 |
Synaptec Development Llc |
GALANTAMINE CLEARANCE OF AMYLOID ß
|
US20180194861A1
(en)
|
2015-07-10 |
2018-07-12 |
Abbvie Inc. |
IgM- or IgE-Modified Binding Proteins and Uses Thereof
|
WO2017058866A1
(en)
|
2015-09-28 |
2017-04-06 |
Precision Immune, Inc. |
Anti-trem2 antibodies and uses thereof
|
KR20180068999A
(ko)
*
|
2015-10-06 |
2018-06-22 |
알렉터 엘엘씨 |
항-trem2 항체 및 그의 사용방법
|
KR102415925B1
(ko)
*
|
2016-01-11 |
2022-07-04 |
삼성디스플레이 주식회사 |
표시장치
|
US11066456B2
(en)
|
2016-02-25 |
2021-07-20 |
Washington University |
Compositions comprising TREM2 and methods of use thereof
|
JP2019531332A
(ja)
|
2016-07-22 |
2019-10-31 |
ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー.ファウ.(デーツェットエンエー) |
Trem2切断モジュレーター及びその使用
|
SG11201900744SA
(en)
|
2016-08-12 |
2019-02-27 |
Janssen Biotech Inc |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
US20190367623A1
(en)
|
2017-01-17 |
2019-12-05 |
Yeda Research And Development Co. Ltd. |
Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
|
WO2018140831A2
(en)
|
2017-01-27 |
2018-08-02 |
Silverback Therapeutics, Inc. |
Tumor targeting conjugates and methods of use thereof
|
US10457717B2
(en)
|
2017-02-17 |
2019-10-29 |
Denali Therapeutics Inc. |
Engineered polypeptides
|
JOP20190248A1
(ar)
*
|
2017-04-21 |
2019-10-20 |
Amgen Inc |
بروتينات ربط مولد ضد trem2 واستخداماته
|
US20190008812A1
(en)
|
2017-07-07 |
2019-01-10 |
Washington University |
Methods for treating microglial dysfunction
|
JP2020530986A
(ja)
|
2017-07-27 |
2020-11-05 |
ノバルティス アーゲー |
シェダーゼ耐性trem2変異体
|
CR20190486A
(es)
|
2017-08-03 |
2020-02-10 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
EP3601358B1
(en)
|
2017-08-03 |
2023-05-17 |
Alector LLC |
Anti-trem2 antibodies and methods of use thereof
|
US20200277373A1
(en)
|
2017-09-14 |
2020-09-03 |
Denali Therapeutics Inc. |
Anti-trem2 antibodies and methods of use thereof
|
US20200276335A1
(en)
|
2017-10-03 |
2020-09-03 |
Prevail Therapeutics, Inc. |
Gene therapies for lysosomal disorders
|
WO2019079529A1
(en)
|
2017-10-17 |
2019-04-25 |
The Translational Genomics Research Institute |
TREM2 AGONISTS FOR STIMULATING MICROGLIA AND IDENTIFICATION METHODS
|
EP3723803A4
(en)
|
2017-12-12 |
2021-09-15 |
Pionyr Immunotherapeutics, Inc. |
ANTI-TREM2 ANTIBODIES AND RELATED METHODS
|
WO2019161080A1
(en)
|
2018-02-14 |
2019-08-22 |
Yale University |
Compositions for modulation of a trem or treml protein and methods of use
|
CA3172451A1
(en)
*
|
2020-04-03 |
2021-10-07 |
Robert Paul |
Methods of use of anti-trem2 antibodies
|
US20220389097A1
(en)
*
|
2021-05-14 |
2022-12-08 |
Genentech Inc. |
Agonists of TREM2
|